Ironshore Pharmaceuticals & Development, Inc.

32 articles about Ironshore Pharmaceuticals & Development, Inc.

• Ironshore Announces Publication of New Data for JORNAY PM® in the Journal of Child and Adolescent Psychopharmacology

  4/7/2021

  Ironshore Pharmaceuticals Inc. announced the publication of an original paper in the Journal of Child and Adolescent Psychopharmacology that describes new data showing the effect of JORNAY PM® extended-release capsules CII on caregiver strain as measured by the Caregiver Strain Questionnaire.

• Ironshore Announces Publication of New Data for JORNAY PM® in the Journal of Clinical Psychopharmacology

  6/29/2020

  Ironshore Pharmaceuticals Inc. (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc. and a leader in the commercialization of novel treatments for Attention-Deficit/Hyperactivity Disorder (“ADHD”), today announced the publication of an original paper in the Journal of Clinical Psychopharmacology that describes a model that may facilitate dosage optimization of JORNAY PM® (methylphenidate

• Ironshore to Present a Dose Conversion Poster at the 2020 American Society of Clinical Psychopharmacology Virtual Scientific Poster Session

  6/8/2020

  Ironshore Pharmaceuticals Inc. (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc. and a leader in the commercialization of novel treatments for Attention-Deficit/Hyperactivity Disorder (“ADHD”), today announced it is presenting a poster featuring a post-hoc analysis of a Phase 3 trial of children with ADHD comparing the optimized dose JORNAY PM ® (Methylphenidate HCl) to the study par

• Ironshore to Present Posters at the 2020 Neuroscience Education Institute Virtual Scientific Poster Session

  5/12/2020

  Ironshore Pharmaceuticals Inc. (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc. and a leader in the commercialization of novel treatments for Attention-Deficit/Hyperactivity Disorder (“ADHD”), today announced it is presenting two posters featuring new analyses of its novel delayed-release and extended-release methylphenidate formulation.

• Ironshore to Present Four Posters at the 2020 Annual American Professional Society of ADHD and Related Disorders (APSARD) Meeting

  1/16/2020

  Ironshore Pharmaceuticals Inc. (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc. and a leader in the commercialization of novel treatments for Attention-Deficit/Hyperactivity Disorder (“ADHD”), today announced it will present four posters at the 2020 Annual Meeting of The American Professional Society of ADHD and Related Disorders (APSARD) in Washington, D.C., January 17-19, 2020.

• 

  BioSpace Movers & Shakers, Jan. 10

  1/10/2020

  Pharma and biotech companies bolster their executive leadership teams and boards of directors with this week's appointments.

• Ironshore Pharmaceuticals Hires New Chief Financial Officer and Appoints a Chief Commercial Officer

  1/6/2020

  Ironshore Pharmaceuticals Inc. (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc. and a leader in the commercialization of novel treatments for Attention Deficit Hyperactivity Disorder (“ADHD”), today announced the appointment of Mr. Dave Lemus as Chief Financial Officer and the promotion of Mr. Peter Lammers to the position of Chief Commercial Officer.

• Ironshore Pharmaceuticals Partners With Verix to Support Launch of Prescription Medication

  11/5/2019

  Verix (www.verix.com), a global leader in advanced data & analytic solutions for Commercial Operations in the Life Sciences industry, announces that Ironshore Pharmaceuticals Inc. has selected its analytic platform to support the commercialization of Ironshore's prescription medication, launched in the summer of 2019  in the U.S. market.

• Ironshore to Present Data From a Pivotal Trial of JORNAY PM™ (methylphenidate HCl) CII at the 31st Annual International Conference on ADHD

  11/4/2019

  Ironshore Pharmaceuticals Inc. (“Ironshore”), today announced that it will present data from a pivotal trial of JORNAY PM™ (methylphenidate HCl) extended-release capsules CII for the treatment of ADHD in patients 6 years and older and participate as a premier sponsor of the 31st Annual International Conference on ADHD in Philadelphia, November 6-9, 2019.

• Ironshore Pharmaceuticals Recognizes ADHD Awareness Month Through Partnership With CHADD

  10/28/2019

  In recognition of Attention-Deficit/Hyperactivity Disorder (ADHD) Awareness Month, Ironshore Pharmaceuticals Inc. (Ironshore) has partnered with Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD) to sponsor an educational webinar to help elevate awareness of ADHD and highlight the challenges that families experience during the early morning routine.

• Ironshore Pharmaceuticals to Present Data at the 66th Annual AACAP Meeting

  10/16/2019

  Ironshore Pharmaceuticals Inc. (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc. and a leader in the commercialization of novel treatments for Attention-Deficit/Hyperactivity Disorder (“ADHD”), today announced that it will present two posters at the 66th Annual Meeting of the American Academy of Child & Adolescent Psychiatry (AACAP) in Chicago, October 14-19, 2019,

• Back to School With ADHD: How Do Your Mornings Rate?

  9/5/2019

  Ironshore Pharmaceuticals Inc. recently introduced the Rate My Mornings Quiz, an interactive tool designed to help families identify how ADHD affects their mornings.

• ADDING MULTIMEDIA Now Available - JORNAY PM™ (Methylphenidate HCl) CII, the First and Only ADHD Stimulant Dosed in the Evening

  6/18/2019

  Ironshore Pharmaceuticals Inc. (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc. and a leader in the commercialization of novel treatments for Attention Deficit Hyperactivity Disorder (“ADHD”), today announced that JORNAY PM™ (methylphenidate HCl) extended-release capsules CII is now available in the United States.

• Now Available - JORNAY PM™ (Methylphenidate HCl) CII, the First and Only ADHD Stimulant Dosed in the Evening

  6/11/2019

  Novel Drug Delivery Technology Offers Hope to Families Struggling Through Morning Routines

• Ironshore Pharmaceuticals to Showcase JORNAY PM™ (Methylphenidate HCl) CII at the 2019 American Psychiatric Association Meeting

  5/17/2019

  Ironshore Pharmaceuticals (“Ironshore”), a leader in the commercialization of novel treatments for Attention Deficit Hyperactivity Disorder (“ADHD”), today announced that it will present data from a pivotal trial of JORNAY PM™ (methylphenidate) extended-release capsules CII at the 2019 American Psychiatric Association (“APA”) meeting in San Francisco, CA,

• Ironshore Pharmaceuticals Announces Appointment of Dr. Lewis Warrington as Vice President / Head of Medical Affairs

  1/17/2019

  Ironshore Pharmaceuticals (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc. (“Highland”) and a leader in the commercialization of novel treatments for Attention Deficit Hyperactivity Disorder (ADHD), today announced the appointment of Dr. Lewis Warrington to the position of Vice President / Head of Medical Affairs.

• Ironshore to Present Three Posters at the 2019 Annual American Professional Society of ADHD and Related Disorders (APSARD) Meeting

  1/10/2019

  JORNAY PM is expected to be available commercially in the first half of this year.

• Ironshore to Present New Data at The 65TH Annual AACAP Meeting

  10/17/2018

  The AACAP meeting will take place in Seattle, WA, October 22-27, 2018.

• Ironshore Pharmaceuticals Announces Appointment of W. Scott Evangelista as President and Chief Operating Officer

  9/6/2018

  Prior to joining Ironshore, Mr. Evangelista was President of Integrated Engagement Services at Quintiles

• Ironshore Pharmaceuticals Announces Closing of $143 Million Financing

  8/23/2018

  Ironshore Pharmaceuticals & Development, Inc. announced the closing of the previously announced private placement of Senior Secured Notes